HLX11 not checked

Henlius · HLX29

FollowEvery change as it happens, and a Monday email
Stage
in the US
Next date
Phase 1 trial completes
Trials
6 active
7 in total · 4 in the EU
Targets
 

What this is

How it works
How it works isn't classified yet
How it’s given
“Neoadjuvant(q3w/cycle,total 4cycle): HLX11(loading dose of 840 mg IV , followed by 420 mg IV q3w)+trastuzumab(loading dose of 8 mg/kg IV, followed by 6mg/kg IV q3w)+docetaxel(75mg/m2 IV q3w) Adjuvant: doxorubicin( 60 mg/m2 IV q3w)+cyclophosphamide( 600 mg/m2 IV q3w),total 4 cycle; trastuzumab(loading dose of 8mg/m2 IV , followed by 6 mg/m2 IV q3w)+HLX11(loading dose of 840 mg IV , followed by 420…”In the company’s words, NCT05346224 on ClinicalTrials.gov
Tested for
Breast Cancer, Breast Neoplasms, HER2-positive Breast Cancer, Health Adult Subjects
Main trialPhase 3
“This is a phase III, double-blind, randomized, parallel-controlled, multicenter equivalence study to compare the efficacy and safety of pertuzumab biosimilar HLX11 vs. EU-Perjeta® on HER2-positive and HR-negative early-stage or locally advanced breast cancer with a primary tumor \> 2 cm. Patients are random assignment to 2 arms and treatment with either HLX11 or EU-Perjeta® , and received neoadjuvant THP regimen every 3- weeks 4 cycles,adjuvant AC every 3- weeks 4 cycles and pertuzumab+trastuzumab(HP) every 3- weeks 13cycles.”In the company’s words, NCT05346224 on ClinicalTrials.gov
Other names
HLX29
Copy of
Perjeta (Genentech)Tested side by side with the original in NCT04411550, NCT05346224

Other drugs for Breast Cancer

All 397 drugs for Breast Cancer

Coming up1

Changes0

Last 90 days

No changes yet. We started recording changes on 6 Nov 2026.

Trials7

TrialPhaseCompletesWhat it tests
Phase 3Active, not recruiting 15 May 2024 A Study to Evaluate the Efficacy and Safety of HLX11 vs. EU-Perjeta® in the Neoadjuvant Therapy of HER2-Positive and HR-Negative Early-stage or Locally Advanced Breast Cancer
Phase 1Not yet recruiting 31 Jan 2027 Pharmacokinetic Characteristics, Safety, and Immunogenicity of HLX29 Compared With HLX11
Phase 1Completed 1 Jul 2021 Compare Pharmacokinetics, Safety, and Immunogenicity of HLX11 vs. Perjeta in Healthy Chinese Male Subjects
Phase 2Authorised not given An open-label single arm interventional phase 2 study to investigate outcome of individualized treatment based on pharmacogenomic profiling and ex vivo drug sensitivity testing of patient-derived organoids in patients with metastatic colorectal cancer
Phase 3Authorised not given Diagnostic HER2DX-guided trEatment For patIeNts wIth early-sTage HER2-positIVE breast cancer
Phase 2Authorised not given Anti-HER2 treatment Discontinuation Guided by ctDNA in Patients with HER2-Positive Metastatic Breast Cancer with Sustained Disease Control: PHENIX Trial
Phase 2Authorised not given Optimization of De-EscalatiON strategies in early breast cancer
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026

Follow HLX11

Following is part of Solo: you see every change to HLX11 the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in